Search Results

4SC-202 50mg 50mg  | Purity Not Available

Adooq Bioscience

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.

More Information Supplier Page

4SC-202 25mg 25mg  | Purity Not Available

Adooq Bioscience

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.

More Information Supplier Page

4SC-202 10mM * 1mL in DMSO 10mM * 1mL in DMSO  | Purity Not Available

Adooq Bioscience

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.

More Information Supplier Page

4SC-202 10mg 10mg  | Purity Not Available

Adooq Bioscience

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.

More Information Supplier Page

LuAE58054 25mg 25mg  | Purity Not Available

Adooq Bioscience

LuAE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia.

More Information Supplier Page

LuAE58054 5mg 5mg  | Purity Not Available

Adooq Bioscience

LuAE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia.

More Information Supplier Page